Difusion

ZFUZE biomaterial technology that shifts macrophage response from inflammatory M1 to healing-promoting M2 phenotype, enabling better bone fusion and reduced inflammation in spinal implants.

ZFUZE has received FDA clearance and demonstrated 92.8% fusion rate at 8 months in a retrospective spinal fusion study of 693 patients.